Breaking News Instant updates and real-time market news.

HAS

Hasbro

$76.16

-0.46 (-0.60%)

, P

Pandora

$12.83

-0.34 (-2.58%)

08:58
10/17/16
10/17
08:58
10/17/16
08:58

On The Fly: Pre-market Movers

HIGHER: Omeros (OMER), up 20% after the company reported that statistical significance was achieved on key endpoints in the company's Phase 2 clinical trial of OMS721 for the treatment of kidney disorders... AMD (AMD), up 3.5% after Oppenheimer analyst Rick Schafer upgraded the stock to Perform from Underperform, citing lower balance sheet risk and improved near-term sales trends ahead of the company's Q3 results... Groupon (GRPN), up 5.5% after the stock was upgraded to Outperform from Neutral at Wedbush... Quality Systems (QSII), up 6.5% after Dealreporter reported Friday that the company hired UBS (UBS) to explore a potential sale... Intersect ENT (XENT), up 8.5% after reporting that its clinical trial designed to assess the safety and efficacy of the company's investigational RESOLVE steroid releasing implant met both primary efficacy endpoints. UP AFTER EARNINGS: Hasbro (HAS), up 4%... Bank of America (BAC), up 1.4%. LOWER: Pandora (P), down 3.75% after BofA Merrill Lynch analyst Nat Schindler downgraded the stock to Underperform from Neutral... PTC Therapeutics (PTCT), down 21% after FDA denies first appeal of refuse-to-file letter for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy... Melco Crown Entertainment (MPEL), down 5% after Chinese authorities confirmed they have detained several employees of Crown Resorts, one of Australia's biggest casino operators. Melco Crown is a 27% shareholder in Crown Resorts, The Wall Street Journal noted, adding that stocks of Macau-based casinos listed on the Hong Kong market slid on the news as well. Macau casino operators listed in the U.S. include Las Vegas Sands (LVS), MGM Resorts (MGM) and Wynn Resorts (WYNN).

HAS

Hasbro

$76.16

-0.46 (-0.60%)

P

Pandora

$12.83

-0.34 (-2.58%)

BAC

Bank of America

$16.00

0.17 (1.07%)

OMER

Omeros

$7.34

-0.44 (-5.66%)

AMD

AMD

$6.75

0.26 (4.01%)

PTCT

PTC Therapeutics

$13.27

-0.3 (-2.21%)

GRPN

Groupon

$5.01

0.11 (2.24%)

MPEL

Melco Crown

$15.52

-0.24 (-1.52%)

LVS

Las Vegas Sands

$57.73

-0.36 (-0.62%)

MGM

MGM Resorts

$25.75

-0.31 (-1.19%)

WYNN

Wynn Resorts

$93.37

-1.58 (-1.66%)

QSII

Quality Systems

$11.48

0.28 (2.50%)

XENT

Intersect ENT

$16.60

0.1 (0.61%)

  • 17

    Oct

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 14

    Nov

  • 17

    Nov

  • 29

    Nov

  • 13

    Jan

HAS Hasbro
$76.16

-0.46 (-0.60%)

07/19/16
PIPR
07/19/16
UPGRADE
Target $88
PIPR
Overweight
Hasbro upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Stephanie Wissink upgraded Hasbro to Overweight saying the recent pullback in shares provides an opportunity to buy for "holiday 2016 and full year 2017 drivers." Momentum should return to Hasbro business, led by girls and games in the second half of 2016, Wissink tells investors in a research note. The analyst keeps an $88 price target for the shares.
05/10/16
05/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wayfair (W) downgraded to Neutral at Citi by analyst Mark May, who said international investments and aggressive hiring are likely to limit EBITDA upside in 2016. 2. SolarCity (SCTY) downgraded to Neutral at BofA/Merrill by analyst Krish Sankar, who said the company's strategy to manage growth and costs, and long-term economic value creation has become increasingly unclear. He also said the cost strategy will be impacted by numerous factors including the policy environment, financing and execution risks. The company was also downgraded to Market Perform at Avondale. 3. Hasbro (HAS) downgraded to Neutral at Piper Jaffray with analyst Stephanie Wissink citing limited upside to her unchanged price target of $88. 4. Nike (NKE) resumed with a Market Perform at Wells Fargo by analyst Tom Nikic, who said the company's near-term financials "may prove to be fairly noisy" due to the upcoming Summer Olympics in Brazil. The analyst adds that Nike is facing a level of competition that it has not experienced in quite some time. 5. Sprouts Farmers Markets (SFM) downgraded to Sell at Goldman with analyst Stephen Grambling saying both thee consensus estimates and the valuation are overly optimistic. He said that increasing competition caused the company's comp growth to stall. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/16
PIPR
05/10/16
DOWNGRADE
Target $88
PIPR
Neutral
Hasbro downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Stephanie Wissink downgraded Hasbro to Neutral citing limited upside to her unchanged price target of $88. The analyst notes she's not a seller of the shares as she believes Hasbro deserves a premium multiple.
07/19/16
07/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Outperform from Underperform at CLSA with analyst Jeremy Scott saying the Chiptopia loyalty program is a highly compelling and engaging platform that re-energized its most loyal customers while providing a large-scale acquisition of customer data. 2. Hasbro (HAS) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stephanie Wissink saying the recent pullback in shares provides an opportunity to buy for "holiday 2016 and full year 2017 drivers." 3. IDEX Corp. (IEX) upgraded to Buy from Neutral at Janney Capital with analyst Michael Gaugler saying the company's commentary that North American industrial end markets are showing signs of stabilization was probably more relevant than the second quarter results. 4. Ethan Allen (ETH) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Cristina Fernandez saying Ethan Allen has renewed sales momentum and sees several initiatives in the next few quarters that could sustain sales and drive shares higher. 5. Tesoro (TSO) upgraded to Buy from Neutral at Citi with analyst Faisel Khan saying the shares are trading at a significant discount to net asset value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
P Pandora
$12.83

-0.34 (-2.58%)

10/04/16
GSCO
10/04/16
UPGRADE
Target $19
GSCO
Conviction Buy
Pandora upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Heath Terry added Pandora to the Conviction Buy List and raised his price target to $19 from $17. Terry sees sees significant upside to out-year estimates from premium radio and on-demand subscriptions. He expects competition to ease as new entrants slow and existing providers focus on profitability and limit "free" models.
10/14/16
JPMS
10/14/16
NO CHANGE
Target $134
JPMS
Overweight
JPMorgan tweaks Alibaba, Netflix targets lower ahead of Q3 results
JPMorgan analyst Doug Anmuth lowered his price target for Alibaba (BABA) to $134 from $135 and his target for Netflix (NFLX) to $122 from $125 ahead of the Q3 reporting season. Both stocks remain Overweight rated. The analyst slightly lowered his estimates for Alibaba to reflect tougher inventory comps and increased investment spending. He remains positive on the company's overall monetization trends. On Netflix, Anmuth tweaked his 2017 average selling price forecast lower while increasing his investment spend estimate modestly. Within the Internet space, the analyst's top large-cap picks into the quarter are Alphabet (GOOGL), Facebook (FB) and Amazon.com (AMZN). Among small-caps, his top picks into earnings are Yelp (YELP), Pandora (P) and Match Group (MTCH).
10/17/16
BOFA
10/17/16
DOWNGRADE
Target $9
BOFA
Underperform
Pandora downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Nat Schindler downgraded Pandora to Underperform and lowered its price target to $9 from $14. The analyst believes Pandora's $4B revenue 2020 revenue goal will be difficult to achieve as the on-demand subscription streaming market has become increasingly competitive and the user base is fully penetrated. Schindler believes acquisition speculation has supported Pandora's valuation rather than fundamentals and lowered estimates to reflect reduced On-Demand services value given lower gross margin assumptions.
10/04/16
10/04/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CBS (CBS) upgraded to Buy from Sell at UBS with analyst Doug Mitchelson saying he sees any deal with Viacom (VIA) as priced into CBS shares already. He also has increased confidence in consensus estimates for CBS and sees further upside if the national TV ad market and CBS' ratings remain strong. 2. Pandora (P) upgraded to Conviction Buy from Buy at Goldman with analyst Heath Terry saying he sees significant upside to out-year estimates from premium radio and on-demand subscriptions. He expects competition to ease as new entrants slow and existing providers focus on profitability and limit "free" models. 3. Las Vegas Sands (LVS) upgraded to Buy from Neutral at BofA/Merrill with analyst Shaun Kelley saying shares remain fairly under-owned and thinks estimate revisions will move higher due to market momentum, better ROI for Parisian, Cotai infrastructure additions, and optionality from Japan and real estate. 4. KBR (KBR) upgraded to Buy from Hold at Deutsche Bank with analyst Chad Dillard saying yesterday's 10% post-guidance cut selloff is overdone and backward-looking. 5. West Marine (WMAR) upgraded to Buy from Neutral at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BAC Bank of America
$16.00

0.17 (1.07%)

10/11/16
COMP
10/11/16
INITIATION
Target $13
COMP
Neutral
Bank of America initiated with a Neutral at Compass Point
Compass Point analyst Charles Peabody initiated Bank of America with a Neutral and a $13 price target.
10/10/16
OPCO
10/10/16
NO CHANGE
OPCO
Oppenheimer technical analyst upgrades Financials, downgrades Consumer Staples
Oppenheimer technical analyst Ari Wald upgraded the Financials sector to Market Weight and downgraded Consumer Staples to Underweight in next step in the firm's "cyclical rotation road map." Wald identified Ameriprise (AMP), Bank of America (BAC), Citi (C), Goldman Sachs (GS), Lincoln National (LNC) and SunTrust (STI) as six stocks breaking higher that he sees as likely to benefit from internal market rotation.
09/16/16
GSCO
09/16/16
NO CHANGE
Target $19
GSCO
Conviction Sell
Bank of America operating leverage hitting an inflection, says Goldman
Goldman analyst Richard Ramsden believes Bank of America is hitting an inflection point in operating leverage driven by low single digit growth, stable credit, and absolute reductions in the expense base. The analyst believes topline growth will reach approximately 4% annually through to 2018, driven by consumer bank and wealth management initiatives. Ramsden reiterates his Conviction Buy rating on Bank of American and raised his price target to $19 from $17 given the combination of revenue growth and expense discipline.
09/13/16
SOCG
09/13/16
DOWNGRADE
Target $42
SOCG
Sell
Societe Generale cuts Citi to Sell, Bank of America to Hold
Societe Generale downgraded Citi (C) to Sell from Hold and Bank of America (BAC) to Hold from Buy. The firm has a $42 price target for shares of Citi and attributes an increased negative stance on Cards for the downgrade. Societe Generale has a $17 price target for Bank of America and cites revenue growth for the downgrade to Hold. Citi is trading down 86c to $46.93 and Bank of America is trading down 19c to $15.71.
OMER Omeros
$7.34

-0.44 (-5.66%)

06/02/16
CANT
06/02/16
INITIATION
Target $21
CANT
Buy
Omeros initiated with a Buy at Cantor
Target $21.
AMD AMD
$6.75

0.26 (4.01%)

10/12/16
FBCO
10/12/16
UPGRADE
Target $7
FBCO
Neutral
AMD upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst John Pitzer upgraded AMD to Neutral and raised its price target to $7 from $5.50 saying near-term momentum will continue to offset longer-term concerns around lack of scale. The analyst sees catalysts from conservative Q3/Q4 guidance, recent funding that significantly improved the balance sheet and liquidity, flexibility from the renegotiation of WSA, the Zen product launch in 2017, and potential monetization of its valuable IP.
10/07/16
10/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG, Z) initiated with a Buy at Needham. 2. AMD (AMD) initiated with an Equal Weight at Barclays. 3. Aflac (AFL) was initiated with an Underperform at Credit Suisse while the firm also initiated Prudential (PRU) and Assurant (AIZ) with a Neutral. 4. Fifth Third (FITB) initiated with a Neutral at Wedbush. 5. GW Pharmaceuticals (GWPH) initiated with a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/16
OPCO
10/17/16
UPGRADE
OPCO
Perform
AMD upgraded to Perform from Underperform at Oppenheimer
Oppenheimer analyst Rick Schafer upgraded AMD to Perform citing lower balance sheet risk and improved near-term sales trends ahead of the company's Q3 results.
10/12/16
10/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Positive from Negative at OTR Global with the firm saying its checks indicate iPhone 7 launch orders are above last year's model launch, with fourth quarter order gains and stable inventories. 2. Procter & Gamble (PG) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's plans to accelerate Research & Development and advertising spending, as well as recent positive earnings surprises. 3. Barracuda (CUDA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Andrew Nowinski saying the company reported "another strong quarter" and its transition to a subscription-based cloud portfolio is nearly complete. 4. AMD (AMD) upgraded to Neutral from Underperform at Credit Suisse with analyst John Pitzer saying near-term momentum will continue to offset longer-term concerns around lack of scale. 5. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at BMO Capital with analyst Tim Long saying he expects organic revenue growth to return later this year and sees the company's investment in smart public safety software to help expansion beyond hardware. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PTCT PTC Therapeutics
$13.27

-0.3 (-2.21%)

09/20/16
JEFF
09/20/16
NO CHANGE
Target $7
JEFF
Hold
Jefferies thinks eteplirsen approval will have limited impact on PTC
Jefferies analyst Gena Wang believes yesterday's FDA approval of Sarepta Therapeutics' (SRPT) eteplirsen will have a limited impact on PTC Therapeutics (PTCT). While PTC's potential treatment for Duchenne muscular dystrophy ataluren is considered safe, the FDA approval of eteplirsen is mainly based on the marginal increase of dystrophin level and PTC does not have any dystrophin data from Phase 3, Wang tells investors in a research note. Eteplirsen's approval could pressure the FDA to reconsider the review progress of ataluren, but the final outcome would likely remain the same, the analyst contends. She keeps a Hold rating on PTC with a $7 price target. The stock closed yesterday up 21%, or $1.88, to $10.99.
07/26/16
FBCO
07/26/16
DOWNGRADE
Target $6
FBCO
Neutral
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Alethia Young downgraded PTC Therapeutics to Neutral and lowered its price target to $6 from $12 citing further uncertainty around the Eurozone DMD approval case. Following the company's release, Young believes that the approval timelines in EU at the best case are now longer than his original expectations though the drug does remain on the market and lowered his probability of success in EMA to 75% from $100.
10/03/16
BOFA
10/03/16
NO CHANGE
Target $15
BOFA
Buy
PTC Therapeutics price target raised to $15 from $9 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised PTC Therapeutics' price target to $15 from $9 following partner Roche's recruitment for a trial it is conducting to investigate a potential treatment for Spinal Muscular Atrophy, or SMA, patients. Given this advancement, the analyst is raising his probability of approval to 30% from 20% in SMA and maintains his Neutral rating.
07/20/16
WEDB
07/20/16
NO CHANGE
Target $12
WEDB
Neutral
Wedbush staying on sidelines on PTC Therapeutics after NICE issues guidance
Noting that NICE has finalized access for England for PTC Therapeutics' Translarna, Wedbush analyst Heather Behanna said she remains on the sidelines on PTC shares, citing the drug's continued regulatory and pricing risks in Europe. While keeping a Neutral rating and $12 price target on PTC shares, Behanna said she believes it is unlikely that the EMA will pull the drug from the market and sees "meaningful upside" in early 2017 if Translarna can demonstrate a statistically significant positive result in cystic fibrosis.
GRPN Groupon
$5.01

0.11 (2.24%)

10/17/16
WEDB
10/17/16
UPGRADE
Target $6.5
WEDB
Outperform
Groupon upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Aaron Turner upgraded Groupon to Outperform saying he expects the company's "large valuation discrepancy" relative to peers to close following its Q3 earnings report. Accelerating site traffic growth and improving deal inventory should drive better than expected Q3 results for Groupon, Turner tells investors in a research note. He thinks investors will "recalibrate their growth expectations" for the company post the results and upped his price target for the shares to $6.50 from $4.50.
09/26/16
MAXM
09/26/16
NO CHANGE
MAXM
New Yelp structure could be catalyst for takeout, says Maxim
Maxim analyst Tom Forte reiterated his Buy rating on Yelp and the firm raised its price target to $45 from $42 citing the company's dissolution of its dual-share class structure, which removes an obstacle for Yelp being taken over by a potential suitor. Forte noted that Alphabet (GOOG), Amazon (AMZN), and Apple (AAPL) have been cited as potential suitors of Yelp in the past. Forte also noted that Groupon (GRPN), which the firm also has a Buy rating on, will see its dual-share class structure expire at the end of October, which could serve as a catalyst for that stock.
09/29/16
BOSC
09/29/16
INITIATION
BOSC
Neutral
Groupon initiated with a Neutral at Boenning & Scattergood
Boenning & Scattergood analyst Murali Sankar initiated Groupon with a Neutral due to valuation.
09/29/16
09/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens Corning (OC) initiated with a Market Perform at Wells Fargo. 2. Kate Spade (KATE) was initiated with an Outperform at CLSA, while the firm initiated Coach (COH) with a Buy and Michael Kors (KORS) with a Sell. 3. RetailMeNot (SALE) and Groupon (GRPN) initiated with a Neutral at Boenning & Scattergood. 4. Carnival (CCL) initiated with a Hold at Deutsche Bank. 5. D.R. Horton (DHI) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MPEL Melco Crown
$15.52

-0.24 (-1.52%)

09/09/16
DBAB
09/09/16
UPGRADE
Target $17
DBAB
Buy
Melco Crown upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Karen Tang upgraded Melco Crown to Buy saying recent interviews with casino staff members indicate that Macau is at the start of a "mass-led GGR recovery." Both base mass and premium mass are growing again, Tang tells investors in a research note. The analyst raised her price target for the shares to $17 from $14.
09/08/16
MACQ
09/08/16
INITIATION
Target $18.8
MACQ
Outperform
Melco Crown initiated with an Outperform at Macquarie
Macquarie analyst Zibo Chen initiated Melco Crown with an Outperform and $18.80 price target. The analyst is optimistic that Studio City will gradually ramp up by 4Q 2017 thanks to the company's non-gaming franchise; and increased traffic generated by nearby new projects such as the Parisian.
07/19/16
HSBC
07/19/16
UPGRADE
HSBC
Buy
Melco Crown upgraded to Buy from Hold at HSBC
HSBC analysts led by Charlene Liu upgraded Melco Crown to Buy and said suboptimal performance of Studio City is in the price and its gradual ramp-up could lead to higher valuation over time. Liu lowered Melco Crown's price target to $15.50 from $16.60.
07/05/16
BERN
07/05/16
NO CHANGE
BERN
Macau casinos could benefit from Philippines ban, says Bernstein
After the president of the Philippines called for a ban of online gambling, Bernstein says that Macau casinos could benefit from such a ban. The firm notes that online Filipino gambling sites have targeted Chinese gamblers. Bernstein adds that "there have been concerns" that bad debt from VIP junket operators could undermine Macau casinos' balance sheet. However, Bernstein says that it sees no evidence of such a trend, and it remains upbeat o nthe casinos' long-term outlook.Publicly traded Macau casinos include Las Vegas Sands (LVS), Melco Crown (MPEL),MGM Resorts (MGM), and Wynn Resorts (WYNN).
LVS Las Vegas Sands
$57.73

-0.36 (-0.62%)

10/04/16
BOFA
10/04/16
UPGRADE
Target $63
BOFA
Buy
Las Vegas Sands upgraded on expected estimate revisions at BofA/Merrill
BofA/Merrill analyst Shaun Kelley upgraded Las Vegas Sands to Buy and raised its price target to $63 from $52. The analyst said shares remain fairly under-owned and thinks estimate revisions will move higher due to market momentum, better ROI for Parisian, Cotai infrastructure additions, and optionality from Japan and real estate.
09/14/16
09/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying an attractive free cash flow and dividend yield makes the risk/reward attractive at current levels. 2. Fifth Third (FITB) upgraded to Buy from Neutral at Compass Point. 3. F5 Networks (FFIV) upgraded to Outperform from Perform at Oppenheimer with analyst Ittai Kidron saying the company has several potential drivers that could drive year-over-year product revenue growth back into positive territory in fiscal 2017. 4. Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus with analyst John Staszak saying that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. 5. DeVry (DV) upgraded to Outperform from Market Perform at Barrington with analyst Alexander Paris saying management's near-term goal is stabilizing revenue at DeVry University growing enrollment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/16
ARGS
09/14/16
UPGRADE
ARGS
Buy
Las Vegas Sands upgraded on Macau outlook at Argus
As noted earlier, Argus upgraded Las Vegas Sands to Buy from Hold. Analyst John Staszak notes that Macau gross gaming revenue increased year-over-year last month for the first time in over two years. He says that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. Target $67.
10/04/16
BOFA
10/04/16
UPGRADE
BOFA
Buy
Las Vegas Sands upgraded to Buy from Neutral at BofA/Merrill
MGM MGM Resorts
$25.75

-0.31 (-1.19%)

09/28/16
DBAB
09/28/16
NO CHANGE
Target $29
DBAB
Buy
MGM Resorts near-term setup is attractive, says Deutsche Bank
After meeting with management, Deutsche Bank analyst Carlo Santarelli says MGM Resorts' valuation is compelling and the near-term setup is attractive. The company continues to execute on its growth strategies amid solid underlying demand in Las Vegas, Santarelli tells investors in a research note. He keeps a Buy rating on MGM with a $29 price target.
10/05/16
NOMU
10/05/16
NO CHANGE
Target $32
NOMU
Buy
MGM Resorts price target raised to $32 from $28 at Nomura
Nomura analyst Harry Curtis raised MGM Resorts' price target to 32 from $28 to reflect continued pricing upside in Las Vegas, the December opening of National Harbour, Q1 RevPAR growth in Las Vegas, and the Q2 opening of MGM Cotai. Curtis rates MGM Resorts a Buy.
10/06/16
ARGS
10/06/16
UPGRADE
ARGS
Buy
MGM Resorts upgraded to Buy from Hold at Argus
10/06/16
ARGS
10/06/16
UPGRADE
ARGS
Buy
MGM Resorts upgraded on positive outlook at Argus
As noted earlier, Argus upgraded MGM to Buy from Hold. Analyst John Staszak upgraded the stock based on what he sees as "prospects for solid growth in Las Vegas and early signs of recovery in Macau." The analyst believes that investors have not yet "fully recognized" the upbeat signs in Macau, and he thinks that the region will rebound in Q4 and 2017, sparked by the opening of new casinos there. Target $32.
WYNN Wynn Resorts
$93.37

-1.58 (-1.66%)

08/12/16
08/12/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macy's (M) downgraded to Neutral from Outperform at Macquarie with analyst Laurent Vasilescu saying the closure of 100 stores will have a greater impact than the $1B in 2017 sales projected by the company, and could be as much as $1.5B-$2B. 2. Wynn Resorts (WYNN) downgraded to Hold from Buy at Union Gaming. 3. Foot Locker (FL) downgraded to Mixed from Positive at OTR Global with the firm citing store manager checks that indicate product mix is pressuring sale growth. 4. Qualcomm (QCOM) downgraded to Neutral from Positive at Arete. 5. Barracuda (CUDA) downgraded to Underperform from Neutral at DA Davidson with analyst Mark Kelleher citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/16
UGAM
08/12/16
DOWNGRADE
UGAM
Hold
Wynn Resorts downgraded to Hold from Buy at Union Gaming
07/29/16
07/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GrubHub (GRUB) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Monness Crespi, and to Hold from Buy at Maxim. 2. Ford (F) downgraded to Neutral from Buy at Goldman with analyst Patrick Archambault saying share outperformance over the next 6-12 months will be difficult following the carmaker's weaker than expected second quarter results and profit warning for 2016. 3. Starz (STRZA) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak saying the Starz/Lionsgate (LGF) pro-forma entity is fairly valued. 4. Western Digital (WDC) downgraded to Hold from Buy at Cross Research with the firm saying the company is either unwilling or unable to provide a reasonable level of precision to the newly combined businesses with SanDisk and the higher than expected cost structure, combined with compensation increases will be a drag. 5. Wynn Resorts (WYNN) downgraded to Reduce from Neutral at Nomura and to Underperform from Outperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/29/16
LYON
07/29/16
DOWNGRADE
LYON
Underperform
CLSA cuts Wynn Resorts to Underperform, says cannibalization risk underestimated
As previously reported, CLSA analyst Jon Oh downgraded Wynn Resorts to Underperform from Outperform. Along with its Q2 call, the company revealed that it expects to receive only 100 new tables for the Wynn Palace opening and expects to move a greater-than-expected 250 tables from Wynn Macau to Wynn Palace. While Oh does not think Wynn Palace's economics change in this scenario, he remains concerned that the market is underestimating the risk of self-cannibalization and a slower Macau EBITDA uplift. Oh keeps a $97 price target on the stock but believes the risk/reward ratio has become unfavorable following the stock's year-to-date rally of over 50%.
QSII Quality Systems
$11.48

0.28 (2.50%)

10/05/16
UBSW
10/05/16
INITIATION
Target $10.5
UBSW
Sell
Quality Systems initiated with a Sell at UBS
Target $10.50.
06/08/16
LEER
06/08/16
NO CHANGE
Target $16
LEER
Market Perform
Pieces in place for Quality Systems turn-around, says Leerink
Leerink analyst David Larsen says he is now incrementally more positive on Quality Systems's stock after attending the company's analyst day. Recurring revenue continues to rise and management is focused on growing earnings, the analyst tells investors in a research note. However, Larsen believes Quality Systems still faces "significant attrition" of its core base, and is worried that Q1 bookings may disappoint. The analyst reiterates a Market Perform rating and $16 price target on the shares as he waits to see more turn-around traction before getting more positive.
10/17/16
BARD
10/17/16
NO CHANGE
Target $14
BARD
Neutral
Quality Systems potential LBO returns not compelling, says Baird
Baird analyst Matthew Gillmor noted Quality Systems has reportedly hired an investment bank to explore a potential sale. However, at current levels he would not chase the stock. Gillmor sees LBO returns as non-compelling and anticipates several risks and challenges for any strategic buyer. Gillmor maintained his Neutral rating and $14 price target on Quality Systems shares, which rose 28c, or 2.5%, to close at $11.48 on Friday.
10/14/16
10/14/16
NO CHANGE

Quality Systems hired UBS to explore a sale, Dealreporter says citing sources
Quality Systems has hired UBS to explore a potential sale, Dealreporter says citing sources. Last week, Quality Systems management conducted presentations for several strategic buyers and financial sponsors, the sources said.
XENT Intersect ENT
$16.60

0.1 (0.61%)

05/20/16
PIPR
05/20/16
NO CHANGE
Target $23
PIPR
Overweight
Intersect ENT selloff feels like an overreaction, says Piper Jaffray
After meeting with Intersect ENT's CEO Lisa Earnhardt, Piper Jaffray analyst Matt O'Brien says the recent pullback in the shares "feels like a bit of an overreaction." The company's sales force has stabilized and Q2 and Q3 revenue estimates look achievable, O'Brien tells investors in a research note. Further, with $4 per share in cash and no debt, Intersect's current stock price implies little, if any, value to its pipeline of products, the analyst argues. He keeps an Overweight rating on the shares with a $23 price target.
08/25/16
PIPR
08/25/16
NO CHANGE
PIPR
Intersect ENT should be owned at current levels, says Piper Jaffray
After meeting with Intersect's management, Piper Jaffray analyst Matt O'Brien says that recent "negative issues" involving sales force disruptions and reimbursement are not "hurting the company much." The analyst says that the company has several growth drivers, and he predicts that they will enable the company's revenue to increase about 20% over the next several years. O'Brien says that the decline in the stock this year is overdone, and he keeps a $21 price target and Overweight rating on the shares.
10/06/16
DBAB
10/06/16
INITIATION
Target $17
DBAB
Hold
Intersect ENT initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Brittany Henderson started Intersect ENT with a Hold rating and $17 price target. The analyst believes risk around the company's execution and reimbursement offsets its differentiated product platform in the near term.
05/06/16
WEDB
05/06/16
NO CHANGE
WEDB
Intersect ENT post-earnings weakness an overreaction, says Wedbush
Wedbush believes that nothing has really changed in the story for Intersect ENT based on the company's quarterly report and thinks today's selloff is an overreaction.

TODAY'S FREE FLY STORIES

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.